NORDIC BIOSCIENCE HOLDING A/S financials

NORDIC BIOSCIENCE HOLDING A/S

Country: DK Reporting currency: DKK Latest annual report: 2024-12-31

LEI: 549300CD4NK2BVJ4VL20

Financial statements (DKK, as reported — unscaled; 78 line items across 3 annual periods)

Line item	2024	2023	2022
Income statement
Revenue	DKK 527.4M	DKK 190.4M	—
Cost of sales	DKK 61.8M	DKK 58.0M	—
Gross profit	DKK 465.6M	DKK 132.4M	—
Other income	DKK 8.4M	DKK 10.8M	—
Administrative expenses	DKK 77.0M	DKK 49.2M	—
Operating profit (EBIT)	DKK 197.7M	-DKK 17.6M	—
Profit before tax	DKK 209.8M	-DKK 21.2M	—
Income tax expense	DKK 39.0M	-DKK 33.5M	—
Profit for the year	DKK 170.8M	DKK 12.3M	—
— attributable to owners	DKK 170.8M	DKK 12.3M	—
— attributable to NCI	DKK 0	DKK 0	—
Total comprehensive income	DKK 170.8M	DKK 16.6M	—
Per share
Basic EPS	DKK 0.16	DKK 0.01	—
Diluted EPS	DKK 0.16	DKK 0.01	—
Free cash flow / share	DKK 0.35	DKK 0.07	—
Cash flow statement
Net cash from operating activities	DKK 379.9M	DKK 76.5M	—
Income taxes paid	DKK 8.7M	DKK 3.1M	—
Net cash from investing activities	-DKK 3.9M	-DKK 10.6M	—
Purchase of PP&E (capex)	DKK 2.6M	DKK 6.6M	—
Purchase of intangibles	DKK 1.3M	DKK 4.0M	—
Net cash from financing activities	-DKK 3.3M	-DKK 44.4M	—
Dividends paid	DKK 0	DKK 40.0M	—
Lease liability payments	DKK 512.0K	DKK 409.0K	—
Net change in cash	DKK 372.7M	DKK 21.5M	—
Balance sheet
Total assets	DKK 720.3M	DKK 288.5M	DKK 228.3M
Non-current assets	DKK 147.0M	DKK 128.8M	DKK 84.5M
Current assets	DKK 573.3M	DKK 159.8M	DKK 143.7M
Inventories	DKK 19.9M	DKK 23.6M	DKK 27.4M
Trade & other receivables	DKK 82.9M	DKK 21.2M	DKK 38.4M
Cash & equivalents	DKK 455.4M	DKK 81.9M	DKK 60.6M
Total equity	DKK 230.9M	DKK 44.1M	DKK 61.6M
— attributable to owners	DKK 230.9M	DKK 44.1M	DKK 62.4M
Non-current liabilities	DKK 40.6M	DKK 46.1M	DKK 45.1M
Lease liabilities (non-current)	DKK 2.4M	DKK 3.1M	DKK 0
Current liabilities	DKK 448.7M	DKK 198.3M	DKK 121.5M
Lease liabilities (current)	DKK 671.0K	DKK 512.0K	DKK 0
Deferred tax liabilities	DKK 1.2M	DKK 3.3M	DKK 2.9M
Derived metrics
Free cash flow	DKK 377.3M	DKK 69.9M	—
Operating margin	37.5%	-9.3%	—
Net margin	32.4%	6.5%	—
Return on equity	74.0%	27.9%	—
Cash conversion ratio	2.22×	6.21×	—
Capex coverage	146.15×	11.64×	—
Other reported items
Comprehensive Income Attributable To Noncontrolling Interests	DKK 0	DKK 0	—
Comprehensive Income Attributable To Owners of Parent	DKK 170.8M	DKK 16.6M	—
Current Accruals and Current Deferred Income Including Current Contract Liabilities	DKK 8.5M	DKK 3.2M	DKK 5.8M
Current Contract Assets	DKK 13.4M	DKK 11.3M	DKK 1.1M
Current Contract Liabilities	DKK 329.0M	DKK 163.5M	DKK 75.0M
Current Prepayments	DKK 0	DKK 1.4M	DKK 3.3M
Current Tax Liabilities Current	DKK 65.6M	DKK 7.5M	DKK 3.1M
Deferred Tax Assets	DKK 67.8M	DKK 42.0M	DKK 0
Effect of Exchange Rate Changes On Cash and Cash Equivalents	DKK 764.0K	-DKK 215.0K	—
Equity and Liabilities	DKK 720.3M	DKK 288.5M	DKK 228.3M
Finance Costs Paid Classified As Operating Activities	DKK 4.0M	DKK 4.0M	—
Finance Income Received Classified As Operating Activities	DKK 10.7M	DKK 4.5M	—
Fixtures and Fittings	DKK 10.9M	DKK 13.2M	DKK 9.2M
Income Tax Relating To Components of Other Comprehensive Income	DKK 0	DKK 0	—
Increase Decrease In Working Capital	-DKK 156.0M	-DKK 77.5M	—
Increase Decrease Through Sharebased Payment Transactions	DKK 16.1M	DKK 7.0M	—
Intangible Assets Other Than Goodwill	DKK 4.1M	DKK 8.0M	DKK 8.4M
Issued Capital	DKK 10.6M	DKK 10.6M	DKK 10.6M
Land and Buildings	DKK 64.3M	DKK 65.6M	DKK 66.9M
Liabilities	DKK 489.4M	DKK 244.5M	DKK 166.6M
Other Adjustments For Noncash Items	DKK 55.1M	-DKK 10.6M	—
Other Comprehensive Income	-DKK 42.0K	DKK 4.3M	—
Other Comprehensive Income Before Tax Exchange Differences On Translation	-DKK 42.0K	DKK 4.3M	—
Other Current Payables	DKK 4.6M	DKK 5.5M	DKK 5.1M
Other Current Receivables	DKK 1.6M	DKK 17.4M	DKK 9.9M
Other Finance Cost	DKK 4.0M	DKK 8.0M	—
Other Finance Income	DKK 16.1M	DKK 4.5M	—
Other Individually Immaterial Components of Other Comprehensive Income Before Tax	DKK 0	DKK 0	—
Payments To Acquire Or Redeem Entitys Shares	DKK 0	DKK 1.2M	—
Purchase of Treasury Shares	—	DKK 1.2M	—
Research and Development Expense	DKK 199.3M	DKK 111.7M	—
Reserve of Exchange Differences On Translation	DKK 3.8M	DKK 3.8M	-DKK 499.0K
Retained Earnings	DKK 216.6M	DKK 29.7M	DKK 52.3M
Trade and Other Current Payables To Trade Suppliers	DKK 37.5M	DKK 15.3M	DKK 29.2M
Trade and Other Current Receivables Due From Related Parties	DKK 0	DKK 2.9M	DKK 3.1M

Methodology

Every line item above is a fact tagged in NORDIC BIOSCIENCE HOLDING A/S's annual report filed in the European Single Electronic Format (ESEF) under the IFRS taxonomy (ifrs-full) — the income statement, balance sheet and cash-flow statement as the filer reported them. Values are shown as-is, in the reporting currency (DKK), without rescaling; the row labels map to the underlying concept name (e.g. Revenue → ifrs-full:Revenue, Operating profit → ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS → ifrs-full:DilutedEarningsLossPerShare), and any concept without a curated label is shown under “Other reported items” with its de-camel-cased tag name. Only consolidated, default-member facts are shown (segment / dimensional breakdowns are excluded).

“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.

Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.